Columbia Laboratories to Present at FTN Midwest Securities Health
Care Conference in NYC on June 6, 2006
LIVINGSTON, NJ— May 31, 2006—Columbia Laboratories, Inc. (NASDAQ: CBRX) announced today that its president and chief executive officer, Robert S. Mills, will present at the upcoming FTN Midwest Securities 2006 Health Care Conference.
| Date: | Tuesday, June 6, 2006 |
| Time: | 3:05 p.m. Eastern Time |
| Venue: | The Four Seasons Hotel, New York City |
| Live webcast: | www.columbialabs.com under "Events" in the Investor section |
A replay of the webcast will be available for 60 days on Columbia Laboratories website, www.columbialabs.com, under “Events” in the Investor section.
About Columbia Laboratories
Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company dedicated to the development and commercialization of women's health care and endocrinology products. Columbia markets Prochieve® 8% (progesterone gel) for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile women with progesterone deficiency and Prochieve® 4% (progesterone gel) for the treatment of secondary amenorrhea. The Company also markets Striant® (testosterone buccal system) for the treatment of hypogonadism in men. Columbia's products and product candidates utilize the Company's bioadhesive drug delivery technology, which is able to deliver a broad range of compounds, including peptides, across many of the body’s mucosal surfaces to address numerous therapeutic areas. The Company is investigating the potential utility of Prochieve® 8% (progesterone gel) in the prevention of preterm birth and developing a vaginally-administered lidocaine product to treat dysmenorrhea and pelvic pain. For more information, please visit www.columbialabs.com.
Prochieve® and Striant® are registered trademarks of Columbia Laboratories, Inc.
###